Historical record - last NADAC effective date: 2/19/2020
Product Information
VENLAFAXINE HCL 37.5 MG TABLET is a generic product labeled by Rising Pharma Holdings Inc., priced at $0.1913 per EA under NDC 57237017390. Its NADAC has been published 102 times since Mar 14, 2018.
FDA first approved this application on Apr 7, 2010. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
37.5 mg/1
Manufacturer
Rising Pharma Holdings Inc.NDC
57237017390
Classification
Generic
Dosage Form
TABLET
Route
ORAL
Effective Date
2/19/2020
Active Ingredients
VENLAFAXINE HYDROCHLORIDEApproval Type
Generic (ANDA)
FDA Application
ANDA090555FDA Approved
4/7/2010
TE Code
AB
On Market Since
4/7/2010
Pharmacological Classes
Price Statistics
The NADAC for VENLAFAXINE HCL 37.5 MG TABLET has been published 102 times since Mar 14, 2018, and over the history we have for it it has declined 18.7%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.1913 per EA |
|---|---|
| All-time high | $0.2469 (Apr 11, 2018) |
| All-time low | $0.1586 (Feb 20, 2019) |
| Median price | $0.1821 |
| Average price | $0.1863 |
| Largest weekly change | +37.6% (Jun 19, 2019) |
| Weeks tracked | 102 |
| Tracking since | Mar 14, 2018 |
1W
N/A
1M
N/A
3M
N/A
6M
N/A
1Y
N/A
3Y
N/A
5Y
N/A
All
-18.7%
Last surveyed Feb 19, 2020 — this NDC no longer appears in the current weekly NADAC file.
Generic Alternatives
The matcher finds 3 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 63% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Rising Pharma Holdings Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
venlafaxine hydrochloride market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Serotonin and Norepinephrine Reuptake Inhibitor class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of VENLAFAXINE HCL 37.5 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for VENLAFAXINE HCL 37.5 MG TABLET, manufactured by Rising Pharma Holdings Inc., is $0.1913 per EA (NDC 57237017390), effective Feb 19, 2020.
How has the price of VENLAFAXINE HCL 37.5 MG TABLET changed over time?
Over the history we have for it, the NADAC for VENLAFAXINE HCL 37.5 MG TABLET has declined 18.7%. It has been tracked across 102 weekly CMS publications since Mar 14, 2018.
What are the highest and lowest recorded NADAC prices for VENLAFAXINE HCL 37.5 MG TABLET?
Since Mar 14, 2018, the NADAC for VENLAFAXINE HCL 37.5 MG TABLET has ranged from a low of $0.1586 (Feb 20, 2019) to a high of $0.2469 (Apr 11, 2018), with a median of $0.1821 per EA.
Are there cheaper alternatives to VENLAFAXINE HCL 37.5 MG TABLET?
Yes. 3 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, VENLAFAXINE HCL 37.5 MG TABLET, is $0.0714 per EA — about 63% below VENLAFAXINE HCL 37.5 MG TABLET.
Who manufactures VENLAFAXINE HCL 37.5 MG TABLET?
VENLAFAXINE HCL 37.5 MG TABLET (NDC 57237017390) is labeled by Rising Pharma Holdings Inc., and CMS classifies it as a generic product.